Streetbeat News

Products Services

AAPL

AMZN

DIS

LLY

NKLA

XLE

Recent economic data and Federal Reserve officials' remarks have led investors to adjust expectations for interest rate cuts, as the U.S. economy shows resilience with job growth and manufacturing expansion. Energy stocks, particularly the Energy Select Sector SPDR Fund, benefited from rising oil prices. Apple is refocusing on home robotics, potentially entering a new market. Disney's board received strong shareholder support, affirming CEO Bob Iger's leadership. Eli Lilly faces supply challenges for its popular weight loss drugs on Amazon Pharmacy. Nikola Corp outperformed other EV stocks, including Tesla, Rivian, and Lucid, highlighting its recovery and focus on hydrogen fuel cell trucks.

Portfolio Pulse from Piero Cingari

April 05, 2024 | 8:23 pm

ABBV

Recent options activity for AbbVie (NYSE:ABBV) shows a bearish sentiment among investors, with 68% of trades being bearish. Significant trades have targeted a price range of $125.0 to $195.0. AbbVie, a pharmaceutical firm, is currently trading at $170.0, up 1.25%, with an RSI suggesting it may be approaching oversold. Analysts from Barclays and Guggenheim maintain positive ratings with target prices of $195 and $190, respectively.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:16 pm

AAPL

VGK

Apple has announced that it will allow music streaming apps in the European Economic Area to provide an external purchase link. This decision, reported by Reuters, marks a significant change in Apple's policy, potentially affecting its revenue from these apps.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:15 pm

ME

23andMe Holding Co. (NASDAQ:ME) will present data on two clinical stage immuno-oncology programs at the AACR Annual Meeting 2024. The programs include 23ME-01473, targeting ULBP6, and 23ME-00610, targeting CD200R1. Both programs aim to enhance anti-tumor immunity, with '1473 focusing on restoring NK and T cell function and '00610 targeting the CD200R1 pathway for potential combination therapies. The presentations will showcase the discovery, preclinical data, and ongoing clinical trials for these antibodies.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:06 pm

OCGN

Ocugen, Inc. (NASDAQ:OCGN) shares rose after announcing approval to proceed with medium dose dosing in the Phase 1/2 study of OCU410. The Data and Safety Monitoring Board for the ArMaDa clinical trial approved this next step, highlighting the therapy's safety and potential as a one-time treatment for life. Ocugen also updated on progress in its gene therapy programs for blindness diseases. The company's stock is up 20%, trading at $1.81.

Portfolio Pulse from Erica Kollmann

April 05, 2024 | 7:56 pm

DKNG

DraftKings shares are trading higher, potentially due to the ongoing NCAA Tournament and overall market strength.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 7:47 pm

TM

TSLA

Tesla Inc (NASDAQ:TSLA) stock fell 3.6% after reports emerged that the company has halted plans for a low-cost vehicle, opting to focus on self-driving technologies instead, a claim CEO Elon Musk denies. A Reddit post compared Tesla's declining growth and high PE ratio unfavorably with Toyota (NYSE:TM), highlighting Tesla's financial challenges, including a dip in auto gross margins and a decline in vehicle deliveries. Technical indicators also suggest a bearish trend for Tesla stock.

Portfolio Pulse from Surbhi Jain

April 05, 2024 | 7:44 pm

GOLD

Barrick Gold Corporation (NYSE:GOLD) shares have risen over 7% in the past five days, buoyed by the record high gold prices reaching $2,330.50 per ounce. The company's expansion includes mines and projects across 18 countries and a new concession request in Puno, Peru. Trading volume for GOLD has significantly exceeded its 100-day average, indicating heightened investor interest.

Portfolio Pulse from Erica Kollmann

April 05, 2024 | 7:37 pm

AXS

RON

Frank Cheng, founder of Foonie Magus, discussed Apeiron's transition from Web2 to Web3, the launch of its ecosystem token APRS, and its appeal to competitive gamers. Apeiron, a Web3 god game, aims to redefine digital gaming with blockchain technology. Cheng highlighted the game's unique battle system, the strategic choice of Ronin (RON) as its blockchain platform, and the potential of the APRS token to create a vibrant economy within the game. The anticipated God Mode is expected to expand gameplay and narrative dimensions, with a launch timeframe in Q3 and Q4.

Portfolio Pulse from Jose Rodrigo Safdiye

April 05, 2024 | 7:34 pm

AZN

The FDA has granted accelerated approval to ENHERTU, a treatment for unresectable or metastatic HER2-positive solid tumors. This decision could significantly impact the drug's availability and use in treating various cancers, marking a pivotal development for patients with these conditions.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 7:30 pm